文献速递临床生化临床免疫

方法特异性皮质醇与地塞米松阈值提高库欣综合征地塞米松抑制试验的临床特异性

Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome.
PubMed 文献 · Clin Chem · 2021-01-01

该研究在400份地塞米松抑制试验(DST)血清样本中同步定量地塞米松和皮质醇,发现地塞米松低于正常下限(1.8 ng/mL)提示依从性差或暴露不足。排除这些样本并采用方法特异性皮质醇阈值2.4 µg/dL后,疑似库欣综合征的临床特异性从67.5%升至92.4%,敏感度保持100%。

要点

  • DST样本同步定量地塞米松可识别未服药或暴露不足导致的假阳性。
  • 地塞米松下限取排除库欣综合征人群的第2.5百分位,为1.8 ng/mL。
  • 方法特异性皮质醇阈值2.4 µg/dL使特异性升至92.4%且敏感度100%。

核心结论

  • 在DST样本中定量地塞米松并采用方法特异性皮质醇阈值,可降低假阳性率并减少需进一步检查的患者比例。

研究设计与样本

  • 在指征组内随机选取400份DST血清样本,包括100例显性库欣综合征、200例排除库欣综合征和100例肾上腺意外瘤伴(可能)自主皮质醇分泌(AI-ACS)。
  • 用液相色谱-串联质谱同步定量地塞米松和皮质醇,以排除库欣综合征患者地塞米松的第2.5百分位为正常下限(LLN)。

主要发现

  • 血清地塞米松范围从检测不到至20.2 ng/mL,中位数4.8 ng/mL(95%CI 4.5-5.1 ng/mL)。
  • 仅16例(4%)地塞米松检测不到,提示不依从。
  • 地塞米松LLN为1.8 ng/mL(4.6 nmol/L)。
  • 肾小球滤过率下降和糖尿病与较高地塞米松浓度相关,而体重指数、性别、年龄、尼古丁和口服避孕药无显著影响。
  • 在疑似库欣综合征样本中排除27份地塞米松<LLN者并采用皮质醇阈值2.4 µg/dL(66 nmol/L)后,临床特异性从67.5%升至92.4%,临床敏感度保持100%。

关键数值与推荐

  • 地塞米松正常下限(LLN)为1.8 ng/mL(4.6 nmol/L),取排除库欣综合征人群的第2.5百分位。
  • 方法特异性皮质醇切点为2.4 µg/dL(66 nmol/L)。
  • 应用上述标准后临床特异性从67.5%升至92.4%,临床敏感度保持100%。
  • 100份AI-ACS样本中,4份地塞米松<1.8 ng/mL,14份皮质醇<2.4 µg/dL,可排除自主皮质醇分泌。

临床怎么用

  • 在DST样本中同步定量地塞米松,可识别未服药或暴露不足所致假阳性。
  • 采用本方法特异性皮质醇阈值2.4 µg/dL并排除地塞米松<1.8 ng/mL的样本,可提高特异性并减少进一步检查。
  • 对AI-ACS样本,地塞米松<1.8 ng/mL或皮质醇<2.4 µg/dL有助于排除自主皮质醇分泌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The dexamethasone suppression test (DST) is the recommended first-tier test for suspected Cushing syndrome (CS). Missed dexamethasone intake or insufficient dexamethasone serum exposure may yield false positive results. Quantification of serum dexamethasone in DST samples may therefore improve test performance. METHODS: Simultaneous quantification of dexamethasone and cortisol by liquid chromatography-tandem mass spectrometry in 400 DST serum samples (100 overt CS, 200 excluded CS, 100 adrenal incidentalomas with (possible) autonomous cortisol secretion, AI-ACS) randomly selected within the indication groups. The 2.5th percentile of dexamethasone in patients with excluded CS was considered the lower limit of normal (LLN). RESULTS: Serum dexamethasone varied from undetectable to 20.2 ng/mL with a median of 4.8 ng/mL (95% CI 4.5-5.1 ng/mL). Dexamethasone was undetectable in only 16 patients (4%), suggesting non-compliance. The dexamethasone LLN was 1.8 ng/mL (4.6 nmol/L). Decreased glomerular filtration rate and diabetes mellitus were associated with higher serum dexamethasone concentration, while body mass index, sex, age, nicotine, and oral contraceptives had no significant effect. By excluding the 27 samples with dexamethasone <LLN and applying the method-specific cortisol cutoff of 2.4 µg/dL (66 nmol/L) to samples with suspected CS, the clinical specificity for CS increased from 67.5% to 92.4% while preserving 100% clinical sensitivity. Among 100 AI-ACS samples (defined by immunoassay), 4 samples had dexamethasone <1.8 ng/mL and 14 samples had cortisol <2.4 µg/dL, which excluded autonomous cortisol secretion. CONCLUSIONS: Quantification of dexamethasone and method-specific cortisol cutoffs in DST samples may reduce the false positive rate and lower the proportion of patients requiring further workup.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Vogg N, Kurlbaum M, Deutschbein T, et al. Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clin Chem. 2021. PMID: 33997885. doi:10.1093/clinchem/hvab056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。